ClinicalTrials.gg
CompletedNCT04345367Updated Jul 8, 2022Results posted

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

A Phase 3 interventional study of Abrocitinib 200 mg and Dupilumab 300 mg in Atopic Dermatitis, sponsored by Pfizer. Completed at 151 sites in 15 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-08.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
727
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 20 studies testing abrocitinib in Dermatitis, Atopic — 5 open to participants now, 5 under way, 2 of them phase 3. abrocitinib · Dermatitis, Atopic.

Enrollment
4th of 20
727 · median 150
Started
2020
with 1 other
Phase 3
10 of 20
2 open now
Registered
11th of 20
by date
Lead sponsor
15 of 20
Pfizer

Among the 20 studies testing abrocitinib in Dermatitis, Atopic, this one is the 4th largest by enrollment, is one of 2 that started in 2020, is one of 10 in phase 3, and was the 11th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

5 of the 20 studies testing abrocitinib in Dermatitis, Atopic are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About abrocitinib

abrocitinib: first FDA approval 2022 (CIBINQO), first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 96 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing abrocitinib in Dermatitis, Atopic, or all of them as a file.
02

Study summary

This is a randomized, double-blind, double-dummy, active-controlled, multi-center study to assess the efficacy and safety of abrocitinib 200 mg (2 x 100 mg tablets) administered orally QD compared with dupilumab 300 mg administered by subcutaneous injection every other week (as per label guidelines) in adult participants on background topical therapy, with moderate to severe AD. The treatment duration is 26 weeks. A total of approximately 600 participants will be enrolled from approximately 220 sites globally. Approximately 600 participants will be randomly assigned to study intervention. There are primary efficacy assessments at Week 2 and Week 4, and a key secondary efficacy assessment at Week 16. Efficacy and safety endpoints will be assessed throughout the entire study. Exploratory endpoints related to hand eczema efficacy will be assessed throughout the study.

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • atopic dermatitis
  • atopic eczema
  • eczema
  • JAK
  • janus kinase
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 years of age or older
  • Diagnosis of chronic atopic dermatitis (AD) for at least 6 months
  • Moderate to severe AD (BSA at least 10%, IGA at least 3, EASI at least 16, and PP-NRS severity score at least 4)
  • Recent history of inadequate response to treatment with medicated topical therapy for AD, or who have required systemic therapies for control of their disease

Exclusion criteria

Exclusion Criteria:

  • Acute or chronic medical or laboratory abnormality that may increase the risk associated with study participation
  • Have increased risk of developing venous thromboembolism
  • Unwilling to discontinue current AD medications prior to the study or require treatment with prohibited medications during the study
  • Prior treatment with systemic JAK inhibitors or IL-4 or IL-13 antagonists including dupilumab, lebrikizumab or tralokinumab
  • Other active non-AD inflammatory skin diseases or conditions affecting skin
  • Medical history including thrombocytopenia, coagulopathy or dysfunction, , current or history of certain infections, lymphoproliferative disorders and other medical conditions at the discretion of the investigator
  • Pregnant or breastfeeding women, or women of who are unwilling to use
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
727 participants (actual)

Study arms

  • Experimental
    Abrocitinib 200 mg plus placebo injection

    Abrocitinib 200 mg daily through Week 26, plus placebo injections every other week through Week 24

    Drug: Abrocitinib 200 mg

  • Active comparator
    Dupilumab 300 mg plus placebo tablets

    Dupilumab 300 mg every other week (2 injections on Day 1) through Week 24, plus placebo tablets daily through Week 26

    Combination Product: Dupilumab 300 mg

Interventions

  • Abrocitinib 200 mg administered as two 100 mg tablets to be taken orally once daily for 26 weeks. Placebo injections will be administered every other week for 24 weeks.

  • Combination productDupilumab 300 mg

    Dupilumab 300 mg administered as a single subcutaneous injection every other week for 24 weeks (2 injections on day 1). Placebo tablets will be administered daily.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2

    The severity of itch (pruritus) due to atopic dermatitis (AD) was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

    Time frame: Week 2

  2. Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4

    EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

    Time frame: Week 4

Secondary outcomes

  1. Percentage of Participants Achieving EASI-90 Response at Week 16

    EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

    Time frame: Week 16

  2. Percentage of Participants Achieving EASI-90 Response at Weeks 2, 8, 12, 20 and 26

    EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

    Time frame: Week 2, 8, 12, 20 and 26

  3. Percentage of Participants Achieving >= 75% Improvement From Baseline in EASI (EASI-75) Response at Weeks 2, 4, 8, 12, 16, 20 and 26

    EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

    Time frame: Week 2, 4, 8, 12, 16, 20 and 26

  4. Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline up to Week 26

    IGA assessed severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, except any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation); 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting.

    Time frame: Week 2, 4, 8, 12, 16, 20 and 26

  5. Percentage of Participants Achieving PP-NRS4 From Baseline at Days 2 to 15

    The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

    Time frame: Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15

  6. Percentage of Participants Achieving PP-NRS4 From Baseline at Week 4, 8, 12, 16, 20 and 26

    The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

    Time frame: Week 4, 8, 12, 16, 20 and 26

  7. Time to Achieve >=4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4)

    The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

    Time frame: Baseline (Day 1) up to Week 30

  8. Percent Change From Baseline in the Percentage (%) Body Surface Area (BSA) Affected at Week 2, 4, 8, 12, 16, 20 and 26

    The extent (%) to which a body region was involved with AD was determined using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Four body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin/genitals) and lower limbs (including buttocks). Total number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual was derived as sum of % BSA across all 4 body regions and ranged from 0 to 100%, with higher values representing greater severity of AD.

    Time frame: Baseline (Day 1), Week 2, 4, 8, 12, 16, 20 and 26

  9. Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Total Score at Week 2, 4, 8, 12, 16, 20 and 26

    SCORAD is a scoring index for AD which combined extent (A), severity (B) and subjective symptoms (C). For A, a rule of 9 was used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region was added to determine A (range: 0-100). B: severity of each sign (erythema; edema/papulation; oozing/crusting; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3); severity scores were added to give B (range: 0-18). C: pruritus and sleep loss, each of these 2 were scored by participant/caregiver using visual analog scale (VAS) where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss were added to give 'C' (range: 0-20). SCORAD total score was calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.

    Time frame: Baseline (Day 1), Week 2, 4, 8, 12, 16, 20 and 26

  10. Change From Baseline in Total Anxiety Score Measured Using the Hospital Anxiety and Depression Scale (HADS) at Week 12,16 and 26

    HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-A assessed state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-A total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety.

    Time frame: Baseline (Day 1), Week 12, 16 and 26

  11. Change From Baseline in Total Depression Score Measured Using the HADS at Week 12,16 and 26

    HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-D assessed the state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression symptoms.

    Time frame: Baseline (Day 1), Week 12, 16 and 26

  12. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 2, 12, 16, 20 and 26

    DLQI is a 10-item questionnaire that measured the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score, ranging from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

    Time frame: Baseline (Day 1), Week 2, 12, 16, 20 and 26

  13. Change From Baseline in EuroQol Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12, 16 and 26

    The EQ-5D-5L is a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score. There were two components to the EQ-5D-5L: a five-item health state profile that assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a VAS that measured health state. EQ-5D VAS was used to record participant's rating for his/her current health-related quality of life state on a vertical VAS with scores ranging from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state.

    Time frame: Baseline (Day 1), Week 12, 16 and 26

  14. Change From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Week 12, 16 and 26

    POEM was a 7-item participant reported outcome measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item was scored as: no days=0, 1-2 days=1, 3-4 days=2, 5-6 days=3 and every day=4. The item scores were added to provide a total score ranging from 0 to 28, where higher score indicated greater severity.

    Time frame: Baseline (Day 1), Week 12, 16 and 26

  15. Change From Baseline in Medical Outcomes Study - Sleep Scale (MOS-Sleep Scale) at Week 12, 16 and 26

    The MOS Sleep Scale is a 12-item measure that is segregated into subscales addressing seven sleep domains (i.e. sleep disturbance, snoring, short of breath or headache, adequacy of sleep, somnolence, sleep problems index I and sleep problems index II). An additional single item assessed quantity of sleep. Each of the sleep domains were scored on a range of 0 to 100, and higher scores indicated worse outcomes. The quantity of sleep scores ranged from 0 to 24 (number of hours slept). Change from baseline scores for each individual sleep domain and quantity of sleep are reported in this outcome measure.

    Time frame: Baseline (Day 1), Week 12, 16 and 26

  16. Change From Baseline in Skin Pain NRS at Week 2, 12, 16, 20 and 26

    The skin pain NRS was a participant reported outcome where participants were asked to rate the "worst skin pain" in the past 24 hours on a 11-point scale from 0=no skin pain to 10=worst skin pain imaginable. Higher scores indicated worse pain.

    Time frame: Baseline (Day 1), Week 2, 12, 16, 20 and 26

  17. Medicated Topical Background Therapy-free Days

    Medicated topical background therapy-free days was defined as number of days where a participant maintained a response of EASI-90 or greater without the use of medicated topical background therapy.

    Time frame: Day 1 up to Week 26

  18. Percentage of Participants Achieving >=4 Points Improvement From Baseline in DLQI at Week 2, 12, 16, 20 and 26

    DLQI was a 10-item questionnaire that measured the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

    Time frame: Week 2, 12, 16, 20 and 26

Other outcomes

  1. Number of Participants With Treatment Emergent Adverse Events (AEs)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a treatment-emergent adverse event (TEAE) if the event started on or after the first dosing day until 28 days post last dose of study drug. AEs included both serious and non-serious AEs.

    Time frame: From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)

  2. Number of Participants With Serious Adverse Events (SAEs) and AEs Leading to Study Discontinuation

    An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; a congenital anomaly/birth defect and other important medical events.

    Time frame: From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)

  3. Number of Participants With Laboratory Abnormalities Meeting Pre-Defined Criteria

    The pre-defined criteria for laboratory parameters included: hemoglobin (\<9 grams per deciliter or decreases to \>=2 below baseline); platelets (\<75\*10\^3 cells per millimeter cube \[mm\^3\]); lymphocytes (\<0.5\*10\^3 cells per mm\^3); neutrophils (\<1\*10\^3 cells per mm\^3); aspartate aminotransferase and alanine aminotransferase (\>3\* upper limit of normal).

    Time frame: From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)

  4. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs including temperature, systolic and diastolic blood pressure, and pulse rate were measured in a seated position after 5 minutes rest. Clinically significant change from baseline in vital signs were determined by the investigator.

    Time frame: From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)

  5. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Data

    A single 12-lead ECG was performed after the participant has rested for at least 10 minutes quietly in the supine position. Clinically significant change from baseline in ECG data was determined by the investigator.

    Time frame: From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)

07

Results

Posted Jul 8, 2022

Participant flow

This was a double-blind, double-dummy, active-controlled study in adult participants with moderate to severe atopic dermatitis. The study was conducted across 143 sites in 15 countries.

Participant flow — Overall Study
MilestoneAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Started362365
Completed327334
Not completed3531
Withdrew: Other34
Withdrew: Medication error without associated adverse event10
Withdrew: Withdrawal by subject1111
Withdrew: Protocol violation43
Withdrew: Lost to follow-up24
Withdrew: Lack of efficacy20
Withdrew: Death20
Withdrew: Adverse event109

Outcome measures

PrimaryPercentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2

The severity of itch (pruritus) due to atopic dermatitis (AD) was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

Time frame:
Week 2
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 2
Percentage of participantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Percentage of Participants Achieving Greater Than or Equal to (>=) 4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4) From Baseline at Week 248.2 (43.0 to 53.4)25.5 (21.1 to 30.0)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Cochran-Mantel-Haenszel · p = <0.0001 (Cochran-Mantel-Haenszel (CMH) method adjusted by baseline disease severity.) · Estimate of difference: 22.6 · 95% CI 15.8 to 29.5The estimate and confidence interval (CI) for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
PrimaryPercentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4

EASI quantifies severity of AD based on severity of lesion clinical signs and percentage (%) of body surface area (BSA) affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

Time frame:
Week 4
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 4
Percentage of participantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Percentage of Participants Achieving >= 90% Improvement From Baseline in Eczema Area and Severity Index (EASI-90) Response at Week 428.5 (23.8 to 33.2)14.6 (10.9 to 18.2)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Cochran-Mantel-Haenszel · p = <0.0001 (CMH method adjusted by baseline disease severity.) · Estimate of difference: 14.1 · 95% CI 8.2 to 20.0The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
SecondaryPercentage of Participants Achieving EASI-90 Response at Week 16

EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

Time frame:
Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI-90 Response at Week 16
Percentage of participantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Percentage of Participants Achieving EASI-90 Response at Week 1654.3 (49.2 to 59.5)41.9 (36.8 to 47.0)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Cochran-Mantel-Haenszel · p = 0.0008 (CMH method adjusted by baseline disease severity.) · Estimate of difference: 12.5 · 95% CI 5.3 to 19.7The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
SecondaryPercentage of Participants Achieving EASI-90 Response at Weeks 2, 8, 12, 20 and 26

EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

Time frame:
Week 2, 8, 12, 20 and 26
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving EASI-90 Response at Weeks 2, 8, 12, 20 and 26
Percentage of participantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 211.6 (8.3 to 14.9)7.2 (4.5 to 9.8)
Week 845.4 (40.2 to 50.5)25.4 (20.9 to 29.9)
Week 1247.6 (42.5 to 52.8)33.6 (28.7 to 38.5)
Week 2058.4 (53.3 to 63.5)45.7 (40.6 to 50.9)
Week 2654.6 (49.4 to 59.8)47.6 (42.5 to 52.8)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 4.5 · 95% CI 0.2 to 8.7Week 2. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 20.0 · 95% CI 13.2 to 26.9Week 8. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 14.0 · 95% CI 6.9 to 21.1Week 12. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 12.7 · 95% CI 5.5 to 20.0Week 20. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 6.9 · 95% CI -0.4 to 14.3Week 26. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
SecondaryPercentage of Participants Achieving >= 75% Improvement From Baseline in EASI (EASI-75) Response at Weeks 2, 4, 8, 12, 16, 20 and 26

EASI quantifies severity of AD based on severity of lesion clinical signs and % of BSA affected. Severity of clinical signs of AD lesions (erythema, induration/papulation, excoriation and lichenification) were scored separately for each of 4 body regions (head and neck, upper limbs, trunk \[including axillae and groin)\] and lower limbs \[including buttocks\]) on a 4-point scale: 0= absent; 1= mild; 2= moderate; 3= severe. EASI area score was based on % BSA with AD in body region: 0 (0%), 1 (\>0 to \<10%), 2 (10 to \<30%), 3 (30 to \<50%), 4 (50 to \<70%), 5 (70 to \<90%) and 6 (90 to 100%). Total EASI score =0.1\*Ah\*(Eh+Ih+Exh+Lh) + 0.2\*Au\*(Eu+Iu+ExU+Lu) + 0.3\*At\*(Et+It+Ext+Lt) + 0.4\*Al\*(El+Il+Exl+Ll); A = EASI area score; E = erythema; I = induration/papulation; Ex = excoriation; L = lichenification; h = head and neck; u = upper limbs; t = trunk; l = lower limbs. Total EASI score ranged from 0.0 to 72.0, with higher scores indicating greater severity of AD.

Time frame:
Week 2, 4, 8, 12, 16, 20 and 26
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving >= 75% Improvement From Baseline in EASI (EASI-75) Response at Weeks 2, 4, 8, 12, 16, 20 and 26
Percentage of participantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 229.4 (24.7 to 34.1)21.3 (17.1 to 25.5)
Week 457.6 (52.5 to 62.8)36.8 (31.9 to 41.8)
Week 871.0 (66.3 to 75.7)52.8 (47.6 to 57.9)
Week 1276.3 (71.9 to 80.7)61.4 (56.4 to 66.4)
Week 1677.3 (73.0 to 81.7)67.8 (63.0 to 72.6)
Week 2076.1 (71.7 to 80.6)71.1 (66.4 to 75.7)
Week 2673.0 (68.3 to 77.7)72.3 (67.7 to 76.9)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 8.1 · 95% CI 1.8 to 14.4Week 2. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 20.9 · 95% CI 13.8 to 28.0Week 4. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 18.4 · 95% CI 11.4 to 25.3Week 8. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 14.9 · 95% CI 8.2 to 21.5Week 12. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 9.5 · 95% CI 3.0 to 16.0Week 16. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 5.0 · 95% CI -1.4 to 11.5Week 20. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 0.7 · 95% CI -5.9 to 7.2Week 26. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
SecondaryPercentage of Participants Achieving Investigator's Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline up to Week 26

IGA assessed severity of AD on a 5 point scale (0 to 4, higher scores indicate more severity). Scores: 0= clear, except any residual discoloration (post-inflammatory hyperpigmentation and/or hypopigmentation); 1= almost clear, AD not fully cleared- light pink residual lesions (except post-inflammatory hyperpigmentation), just perceptible erythema, papulation/induration lichenification, excoriation, and no oozing/crusting; 2= mild AD with light red lesions, slight but definite erythema, papulation/induration, lichenification, excoriation and no oozing/crusting; 3= moderate AD with red lesions, moderate erythema, papulation/induration, lichenification, excoriation and slight oozing/crusting; 4= severe AD with deep dark red lesions, severe erythema, papulation/induration, lichenification, excoriation and moderate to severe oozing/crusting.

Time frame:
Week 2, 4, 8, 12, 16, 20 and 26
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Investigator's Global Assessment (IGA) Score of 'Clear' or 'Almost Clear' and >=2 Points Improvement From Baseline up to Week 26
Percentage of participantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 214.4 (10.8 to 18.0)7.2 (4.5 to 9.8)
Week 438.0 (32.9 to 43.0)17.6 (13.7 to 21.5)
Week 850.1 (44.9 to 55.3)30.9 (26.2 to 35.7)
Week 1251.8 (46.6 to 57.0)36.0 (31.1 to 40.9)
Week 1655.3 (50.2 to 60.5)42.5 (37.4 to 47.6)
Week 2060.0 (54.9 to 65.1)50.8 (45.7 to 56.0)
Week 2655.6 (50.4 to 60.8)51.1 (46.0 to 56.3)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 7.3 · 95% CI 2.8 to 11.7Week 2. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 20.6 · 95% CI 14.3 to 26.9Week 4. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 19.5 · 95% CI 12.5 to 26.4Week 8. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 15.8 · 95% CI 8.7 to 23.0Week 12. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 13.0 · 95% CI 5.9 to 20.2Week 16. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 9.2 · 95% CI 2.0 to 16.4Week 20. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 4.5 · 95% CI -2.8 to 11.8Week 26. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
SecondaryPercentage of Participants Achieving PP-NRS4 From Baseline at Days 2 to 15

The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

Time frame:
Day 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 and 15
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PP-NRS4 From Baseline at Days 2 to 15
Percentage of participantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Day 211.0 (7.5 to 14.4)3.8 (1.7 to 5.9)
Day 315.1 (11.3 to 18.8)8.6 (5.6 to 11.5)
Day 422.1 (17.7 to 26.4)10.7 (7.5 to 13.9)
Day 526.4 (21.8 to 31.0)11.9 (8.5 to 15.3)
Day 628.4 (23.7 to 33.2)15.5 (11.7 to 19.3)
Day 733.1 (28.2 to 38.1)13.2 (9.7 to 16.8)
Day 836.3 (31.2 to 41.3)14.1 (10.5 to 17.8)
Day 938.5 (33.4 to 43.6)16.9 (12.9 to 20.8)
Day 1040.0 (34.8 to 45.2)18.7 (14.6 to 22.8)
Day 1140.1 (35.0 to 45.3)20.2 (16.0 to 24.4)
Day 1241.5 (36.3 to 46.7)20.2 (16.0 to 24.4)
Day 1344.0 (38.8 to 49.2)21.5 (17.2 to 25.7)
Day 1445.5 (40.3 to 50.8)23.2 (18.8 to 27.6)
Day 1548.6 (43.3 to 53.8)25.6 (21.1 to 30.1)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 7.1 · 95% CI 3.1 to 11.1Day 2. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 6.5 · 95% CI 1.7 to 11.3Day 3. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 11.4 · 95% CI 6.0 to 16.8Day 4. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 14.5 · 95% CI 8.8 to 20.3Day 5. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 12.9 · 95% CI 6.9 to 19.0Day 6. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 19.9 · 95% CI 13.8 to 26.0Day 7. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 22.1 · 95% CI 15.9 to 28.3Day 8. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 21.7 · 95% CI 15.2 to 28.1Day 9. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of other: 21.3 · 95% CI 14.7 to 27.9Day 10. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 20.0 · 95% CI 13.3 to 26.6Day 11. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 21.3 · 95% CI 14.6 to 27.9Day 12. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 22.5 · 95% CI 15.8 to 29.2Day 13. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 22.4 · 95% CI 15.6 to 29.2Day 14. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 22.9 · 95% CI 16.0 to 29.9Day 15. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
SecondaryPercentage of Participants Achieving PP-NRS4 From Baseline at Week 4, 8, 12, 16, 20 and 26

The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

Time frame:
Week 4, 8, 12, 16, 20 and 26
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving PP-NRS4 From Baseline at Week 4, 8, 12, 16, 20 and 26
Percentage of participantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 458.1 (53.0 to 63.3)40.8 (35.7 to 45.8)
Week 865.8 (60.9 to 70.7)52.7 (47.6 to 57.9)
Week 1266.0 (61.1 to 70.9)61.5 (56.5 to 66.5)
Week 1667.2 (62.4 to 72.1)63.6 (58.7 to 68.6)
Week 2065.3 (60.3 to 70.2)63.2 (58.2 to 68.1)
Week 2668.1 (63.2 to 72.9)63.1 (58.1 to 68.0)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 17.3 · 95% CI 10.1 to 24.5Week 4. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 13.0 · 95% CI 6.0 to 20.1Week 8. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 4.4 · 95% CI -2.5 to 11.4Week 12. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 3.6 · 95% CI -3.4 to 10.5Week 16. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 2.0 · 95% CI -4.9 to 9.0Week 20. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 5.0 · 95% CI -1.9 to 11.9Week 26. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
SecondaryTime to Achieve >=4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4)

The severity of itch (pruritus) due to AD was assessed using the PP-NRS, a validated horizontal NRS. Participants were asked to assess their worst itching due to AD over the past 24 hours on an NRS with scale ranging from 0 to 10, where 0= no itch and 10= worst itch imaginable. Higher scores indicated worse itch.

Time frame:
Baseline (Day 1) up to Week 30
Reported as:
Median · Days
Time to Achieve >=4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4)
DaysAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Time to Achieve >=4 Points Improvement in Peak Pruritus Numerical Rating Scale (PP-NRS4)11.0 (9.0 to 14.0)25.0 (21.0 to 30.0)
SecondaryPercent Change From Baseline in the Percentage (%) Body Surface Area (BSA) Affected at Week 2, 4, 8, 12, 16, 20 and 26

The extent (%) to which a body region was involved with AD was determined using handprint method. Number of handprints (size of participant's hand with fingers in a closed position) fitting in the affected area of a body region was estimated. Four body regions were evaluated: head and neck, upper limbs, trunk (including axillae and groin/genitals) and lower limbs (including buttocks). Total number of handprints were 10 for head and neck, 20 for upper limbs, 30 for trunk and 40 for lower limbs. Surface area of body region equivalent to 1 handprint: 1 handprint was equal to 10% for head and neck, 5% for upper limbs, 3.33% for trunk and 2.5% for lower limbs. Percent BSA for a body region was calculated as = total number of handprints in a body region \* % surface area equivalent to 1 handprint. Overall % BSA for an individual was derived as sum of % BSA across all 4 body regions and ranged from 0 to 100%, with higher values representing greater severity of AD.

Time frame:
Baseline (Day 1), Week 2, 4, 8, 12, 16, 20 and 26
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in the Percentage (%) Body Surface Area (BSA) Affected at Week 2, 4, 8, 12, 16, 20 and 26
Percent changeAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 2-42.7 (-46.0 to -39.4)-33.4 (-36.7 to -30.0)
Week 4-62.0 (-65.5 to -58.5)-49.5 (-53.0 to -46.1)
Week 8-74.0 (-77.2 to -70.7)-62.8 (-66.0 to -59.7)
Week 12-78.8 (-81.9 to -75.7)-69.4 (-72.5 to -66.4)
Week 16-80.6 (-83.5 to -77.8)-73.7 (-76.5 to -70.9)
Week 20-82.2 (-84.8 to -79.6)-76.9 (-79.5 to -74.3)
Week 26-82.3 (-85.0 to -79.6)-79.0 (-81.6 to -76.3)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -9.3 · 95% CI -14.0 to -4.6Week 2. Analysis was performed using Mixed Model Repeated Measure (MMRM) with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -12.5 · 95% CI -17.4 to -7.6Week 4. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -11.1 · 95% CI -15.6 to -6.6Week 8. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -9.4 · 95% CI -13.7 to -5.1Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -6.9 · 95% CI -10.9 to -2.9Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -5.3 · 95% CI -9.0 to -1.7Week 20. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -3.4 · 95% CI -7.1 to 0.4Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
SecondaryPercent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Total Score at Week 2, 4, 8, 12, 16, 20 and 26

SCORAD is a scoring index for AD which combined extent (A), severity (B) and subjective symptoms (C). For A, a rule of 9 was used to calculate BSA affected by AD as % of whole BSA for each body region- head and neck 9%; upper limbs 9% each; lower limbs 18% each; anterior trunk 18%; back 18%; genitals 1%. Score of each body region was added to determine A (range: 0-100). B: severity of each sign (erythema; edema/papulation; oozing/crusting; excoriation; skin thickening; dryness) was assessed as none (0), mild (1), moderate (2), severe (3); severity scores were added to give B (range: 0-18). C: pruritus and sleep loss, each of these 2 were scored by participant/caregiver using visual analog scale (VAS) where, 0=no itch/no sleep loss and 10=worst imaginable itch/sleep loss, higher scores=worse symptoms. Scores for itch and sleep loss were added to give 'C' (range: 0-20). SCORAD total score was calculated as: A/5+7\*B/2+C; range (0-103); higher values=worse outcome.

Time frame:
Baseline (Day 1), Week 2, 4, 8, 12, 16, 20 and 26
Reported as:
Least squares mean · Percent change
Percent Change From Baseline in the SCORing Atopic Dermatitis (SCORAD) Total Score at Week 2, 4, 8, 12, 16, 20 and 26
Percent changeAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 2-44.5 (-47.0 to -42.1)-33.5 (-35.9 to -31.0)
Week 4-59.6 (-61.9 to -57.3)-46.8 (-49.1 to -44.5)
Week 8-65.8 (-68.2 to -63.4)-55.6 (-58.0 to -53.3)
Week 12-67.9 (-70.2 to -65.6)-60.6 (-62.9 to -58.3)
Week 16-70.6 (-72.8 to -68.3)-64.4 (-66.7 to -62.2)
Week 20-71.8 (-74.1 to -69.4)-66.8 (-69.1 to -64.5)
Week 26-71.5 (-73.9 to -69.1)-68.2 (-70.6 to -65.9)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -11.0 · 95% CI -14.5 to -7.6Week 2. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -12.8 · 95% CI -16.0 to -9.5Week 4. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -10.2 · 95% CI -13.6 to -6.8Week 8. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -7.3 · 95% CI -10.5 to -4.1Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -6.1 · 95% CI -9.3 to -3.0Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -4.9 · 95% CI -8.2 to -1.7Week 20. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -3.3 · 95% CI -6.6 to 0.1Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
SecondaryChange From Baseline in Total Anxiety Score Measured Using the Hospital Anxiety and Depression Scale (HADS) at Week 12,16 and 26

HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-Anxiety (HADS-A) scale and HADS-Depression (HADS-D) scale, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-A assessed state of generalized anxiety (anxious mood, restlessness, anxious thoughts, panic attacks). HADS-A total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of anxiety) to 21 (severe feeling of anxiety); higher score indicated greater severity of anxiety.

Time frame:
Baseline (Day 1), Week 12, 16 and 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Anxiety Score Measured Using the Hospital Anxiety and Depression Scale (HADS) at Week 12,16 and 26
Units on a scaleAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 12-0.8 (-1.1 to -0.5)-0.8 (-1.1 to -0.6)
Week 16-1.1 (-1.3 to -0.8)-1.2 (-1.4 to -0.9)
Week 26-1.1 (-1.4 to -0.7)-1.2 (-1.5 to -0.9)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.0 · 95% CI -0.4 to 0.4Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.1 · 95% CI -0.3 to 0.5Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.1 · 95% CI -0.3 to 0.6Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
SecondaryChange From Baseline in Total Depression Score Measured Using the HADS at Week 12,16 and 26

HADS was a validated 14-item questionnaire to assess states of anxiety and depression over the past week. HADS consisted of 2 subscales: HADS-A scale and HADS-D scale, each of which comprised of 7 items. Each item was rated on a 4-point scale, with scores ranging from 0 to 3, where higher scores indicated more anxiety/depression symptoms. HADS-D assessed the state of lost interest and diminished pleasure response (lowering of hedonic tone). HADS-D: total score was calculated as the sum of all 7 items with score ranging from 0 (no presence of depression) to 21 (severe feeling of depression); higher score indicated greater severity of depression symptoms.

Time frame:
Baseline (Day 1), Week 12, 16 and 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Total Depression Score Measured Using the HADS at Week 12,16 and 26
Units on a scaleAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 12-0.7 (-1.0 to -0.5)-0.7 (-1.0 to -0.5)
Week 16-0.8 (-1.0 to -0.5)-0.9 (-1.1 to -0.7)
Week 26-0.8 (-1.0 to -0.5)-1.0 (-1.3 to -0.8)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.0 · 95% CI -0.3 to 0.3Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.1 · 95% CI -0.2 to 0.5Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.2 · 95% CI -0.1 to 0.6Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 2, 12, 16, 20 and 26

DLQI is a 10-item questionnaire that measured the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score, ranging from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

Time frame:
Baseline (Day 1), Week 2, 12, 16, 20 and 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score at Week 2, 12, 16, 20 and 26
Units on a scaleAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 2-8.6 (-9.1 to -8.2)-6.7 (-7.1 to -6.2)
Week 12-10.7 (-11.1 to -10.2)-9.7 (-10.1 to -9.3)
Week 16-10.8 (-11.2 to -10.4)-10.0 (-10.5 to -9.6)
Week 20-10.8 (-11.2 to -10.3)-10.1 (-10.6 to -9.7)
Week 26-10.3 (-10.8 to -9.9)-10.0 (-10.5 to -9.6)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -2.0 · 95% CI -2.6 to -1.3Week 2. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -1.0 · 95% CI -1.6 to -0.4Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.8 · 95% CI -1.4 to -0.2Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.6 · 95% CI -1.2 to 0.0Week 20. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.3 · 95% CI -1.0 to 0.4Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
SecondaryChange From Baseline in EuroQol Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12, 16 and 26

The EQ-5D-5L is a self-reported health status questionnaire that consisted of six questions used to calculate a health utility score. There were two components to the EQ-5D-5L: a five-item health state profile that assessed mobility, self-care, usual activities, pain/discomfort, and anxiety/depression used to obtain an Index Utility Score, as well as a VAS that measured health state. EQ-5D VAS was used to record participant's rating for his/her current health-related quality of life state on a vertical VAS with scores ranging from 0 to 100, where 0 = worst imaginable health state and 100 = best imaginable health state.

Time frame:
Baseline (Day 1), Week 12, 16 and 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in EuroQol Quality of Life 5-Dimension 5-Level (EQ-5D-5L) Visual Analog Scale (VAS) Score at Week 12, 16 and 26
Units on a scaleAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 1212.370 (10.917 to 13.822)11.552 (10.123 to 12.981)
Week 1612.567 (11.015 to 14.118)10.474 (8.951 to 11.997)
Week 2613.484 (11.982 to 14.985)14.300 (12.836 to 15.764)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.818 · 95% CI -1.220 to 2.856Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 2.093 · 95% CI -0.081 to 4.267Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.816 · 95% CI -2.914 to 1.281Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
SecondaryChange From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Week 12, 16 and 26

POEM was a 7-item participant reported outcome measure used to assess the impact of AD (dryness, itching, flaking, cracking, sleep loss, bleeding and weeping) over the past week. Each item was scored as: no days=0, 1-2 days=1, 3-4 days=2, 5-6 days=3 and every day=4. The item scores were added to provide a total score ranging from 0 to 28, where higher score indicated greater severity.

Time frame:
Baseline (Day 1), Week 12, 16 and 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Patient-Oriented Eczema Measure (POEM) Total Score at Week 12, 16 and 26
Units on a scaleAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 12-14.2 (-14.9 to -13.6)-12.6 (-13.3 to -12.0)
Week 16-14.2 (-14.8 to -13.6)-12.8 (-13.4 to -12.2)
Week 26-13.8 (-14.5 to -13.1)-13.4 (-14.0 to -12.7)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -1.6 · 95% CI -2.5 to -0.7Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -1.4 · 95% CI -2.2 to -0.5Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.4 · 95% CI -1.3 to 0.5Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
SecondaryChange From Baseline in Medical Outcomes Study - Sleep Scale (MOS-Sleep Scale) at Week 12, 16 and 26

The MOS Sleep Scale is a 12-item measure that is segregated into subscales addressing seven sleep domains (i.e. sleep disturbance, snoring, short of breath or headache, adequacy of sleep, somnolence, sleep problems index I and sleep problems index II). An additional single item assessed quantity of sleep. Each of the sleep domains were scored on a range of 0 to 100, and higher scores indicated worse outcomes. The quantity of sleep scores ranged from 0 to 24 (number of hours slept). Change from baseline scores for each individual sleep domain and quantity of sleep are reported in this outcome measure.

Time frame:
Baseline (Day 1), Week 12, 16 and 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Medical Outcomes Study - Sleep Scale (MOS-Sleep Scale) at Week 12, 16 and 26
Units on a scaleAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Quantity Hours Slept Score: Week 120.7 (0.5 to 0.9)0.5 (0.2 to 0.7)
Quantity Hours Slept Score: Week 160.6 (0.3 to 0.8)0.5 (0.3 to 0.7)
Quantity Hours Slept Score: Week 260.5 (0.3 to 0.7)0.4 (0.2 to 0.6)
Short of Breath or Headache score: Week 12-0.7 (-2.2 to 0.9)-1.9 (-3.4 to -0.4)
Short of Breath or Headache score: Week 16-1.2 (-2.7 to 0.3)-1.3 (-2.8 to 0.2)
Short of Breath or Headache score: Week 26-2.0 (-3.5 to -0.6)-2.6 (-4.0 to -1.2)
Snoring Score: Week 12-5.3 (-7.0 to -3.6)-3.5 (-5.2 to -1.8)
Snoring Score: Week 16-4.9 (-6.6 to -3.1)-4.0 (-5.7 to -2.3)
Snoring Score: Week 26-3.9 (-5.7 to -2.0)-4.7 (-6.5 to -2.9)
Sleep Disturbance Score: Week 12-20.5 (-22.3 to -18.8)-16.4 (-18.1 to -14.7)
Sleep Disturbance Score: Week 16-21.5 (-23.2 to -19.7)-17.7 (-19.4 to -16.0)
Sleep Disturbance Score: Week 26-21.2 (-23.0 to -19.5)-19.5 (-21.2 to -17.8)
Sleep Adequacy Score: Week 1213.9 (12.1 to 15.8)12.9 (11.1 to 14.7)
Sleep Adequacy Score: Week 1615.7 (13.9 to 17.4)12.7 (11.0 to 14.5)
Sleep Adequacy Score: Week 2614.0 (12.1 to 15.8)13.2 (11.4 to 15.1)
Sleep Somnolence Score: Week 12-7.7 (-9.1 to -6.2)-6.9 (-8.3 to -5.5)
Sleep Somnolence Score: Week 16-9.8 (-11.3 to -8.4)-7.4 (-8.8 to -6.0)
Sleep Somnolence Score: Week 26-9.9 (-11.3 to -8.5)-7.6 (-9.0 to -6.2)
Sleep Problems Index I Score: Week 12-12.1 (-13.4 to -10.8)-10.9 (-12.2 to -9.6)
Sleep Problems Index I Score: Week 16-13.3 (-14.5 to -12.0)-11.0 (-12.2 to -9.8)
Sleep Problems Index I Score: Week 26-12.9 (-14.2 to -11.7)-12.1 (-13.3 to -10.9)
Sleep Problems Index II Score: Week 12-14.4 (-15.7 to -13.1)-12.2 (-13.5 to -10.9)
Sleep Problems Index II Score: Week 16-15.7 (-17.0 to -14.4)-12.8 (-14.0 to -11.5)
Sleep Problems Index II Score: Week 26-15.4 (-16.7 to -14.1)-14.0 (-15.2 to -12.7)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.2 · 95% CI -0.1 to 0.6Quantity of hours slept: Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.1 · 95% CI -0.2 to 0.4Quantity of hours slept: Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.1 · 95% CI -0.2 to 0.4Quantity of hours slept: Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 1.2 · 95% CI -0.9 to 3.4Short of Breath or Headache score: Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.1 · 95% CI -2.0 to 2.2Short of Breath or Headache score: Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.6 · 95% CI -1.5 to 2.6Short of Breath or Headache score: Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -1.8 · 95% CI -4.2 to 0.5Snoring score: Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.9 · 95% CI -3.3 to 1.5Snoring score: Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.8 · 95% CI -1.7 to 3.4Snoring score: Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -4.1 · 95% CI -6.6 to -1.6Sleep disturbance score: Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -3.8 · 95% CI -6.2 to -1.4Sleep disturbance score: Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -1.7 · 95% CI -4.1 to 0.7Sleep disturbance score: Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 1.0 · 95% CI -1.6 to 3.6Sleep adequacy score: Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 2.9 · 95% CI 0.4 to 5.4Sleep adequacy score: Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 0.7 · 95% CI -1.9 to 3.4Sleep adequacy score: Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.8 · 95% CI -2.8 to 1.3Sleep somnolence score: Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -2.4 · 95% CI -4.4 to -0.4Sleep somnolence score: Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -2.3 · 95% CI -4.3 to -0.3Sleep somnolence score: Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -1.2 · 95% CI -3.0 to 0.7Sleep Problems Index I score: Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -2.3 · 95% CI -4.0 to -0.5Sleep Problems Index I score: Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.8 · 95% CI -2.5 to 0.9Sleep Problems Index I score: Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -2.2 · 95% CI -4.0 to -0.3Sleep Problems Index II score: Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -2.9 · 95% CI -4.8 to -1.1Sleep Problems Index II score: Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -1.4 · 95% CI -3.2 to 0.4Sleep Problems Index II score: Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
SecondaryChange From Baseline in Skin Pain NRS at Week 2, 12, 16, 20 and 26

The skin pain NRS was a participant reported outcome where participants were asked to rate the "worst skin pain" in the past 24 hours on a 11-point scale from 0=no skin pain to 10=worst skin pain imaginable. Higher scores indicated worse pain.

Time frame:
Baseline (Day 1), Week 2, 12, 16, 20 and 26
Reported as:
Least squares mean · Units on a scale
Change From Baseline in Skin Pain NRS at Week 2, 12, 16, 20 and 26
Units on a scaleAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 2-3.7 (-3.9 to -3.4)-2.6 (-2.8 to -2.3)
Week 12-4.5 (-4.7 to -4.2)-4.0 (-4.3 to -3.8)
Week 16-4.4 (-4.7 to -4.2)-4.2 (-4.4 to -4.0)
Week 20-4.8 (-5.0 to -4.5)-4.5 (-4.7 to -4.2)
Week 26-4.5 (-4.8 to -4.3)-4.3 (-4.6 to -4.1)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -1.1 · 95% CI -1.5 to -0.8Week 2. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.4 · 95% CI -0.8 to -0.1Week 12. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.2 · 95% CI -0.6 to 0.1Week 16. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.3 · 95% CI -0.6 to 0.0Week 20. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: -0.2 · 95% CI -0.5 to 0.1Week 26. Analysis was performed using MMRM with fixed factors of treatment, visit, treatment by visit interaction, baseline disease severity, baseline value and an unstructured covariance matrix.
SecondaryMedicated Topical Background Therapy-free Days

Medicated topical background therapy-free days was defined as number of days where a participant maintained a response of EASI-90 or greater without the use of medicated topical background therapy.

Time frame:
Day 1 up to Week 26
Reported as:
Least squares mean · Days
Medicated Topical Background Therapy-free Days
DaysAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Medicated Topical Background Therapy-free Days51.4 (46.0 to 56.8)33.3 (27.9 to 38.7)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Least square mean difference: 18.1 · 95% CI 10.5 to 25.7
SecondaryPercentage of Participants Achieving >=4 Points Improvement From Baseline in DLQI at Week 2, 12, 16, 20 and 26

DLQI was a 10-item questionnaire that measured the impact of skin disease. Each question was evaluated on a 4-point scale (range 0 to 3) where, 0 = not at all, 1= a little, 2= a lot, 3= very much, where higher scores indicated more impact on quality of life. Scores from all 10 questions were added up to give DLQI total score range from 0 (not at all) to 30 (very much). Higher scores indicated more impact on quality of life of participants.

Time frame:
Week 2, 12, 16, 20 and 26
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving >=4 Points Improvement From Baseline in DLQI at Week 2, 12, 16, 20 and 26
Percentage of participantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Week 281.3 (77.2 to 85.4)67.5 (62.6 to 72.4)
Week 1285.4 (81.7 to 89.2)81.4 (77.4 to 85.5)
Week 1682.7 (78.7 to 86.8)84.2 (80.4 to 88.1)
Week 2081.8 (77.7 to 85.9)83.7 (79.8 to 87.6)
Week 2676.6 (72.1 to 81.2)80.8 (76.7 to 84.9)
Statistical analysis
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 13.7 · 95% CI 7.3 to 20.1Week 2. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: 3.9 · 95% CI -1.6 to 9.4Week 12. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: -1.6 · 95% CI -7.1 to 4.0Week 16. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: -2.0 · 95% CI -7.6 to 3.6Week 20. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
  • Abrocitinib 200 mg QD vs Dupilumab 300 mg Q2W · Estimate of difference: -4.2 · 95% CI -10.3 to 1.9Week 26. The estimate and CI for difference were calculated based on the weighted average of difference by disease severity group using the normal approximation of binomial proportions.
Other pre-specifiedNumber of Participants With Treatment Emergent Adverse Events (AEs)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was considered a treatment-emergent adverse event (TEAE) if the event started on or after the first dosing day until 28 days post last dose of study drug. AEs included both serious and non-serious AEs.

Time frame:
From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (AEs)
ParticipantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Number of Participants With Treatment Emergent Adverse Events (AEs)268239
Other pre-specifiedNumber of Participants With Serious Adverse Events (SAEs) and AEs Leading to Study Discontinuation

An SAE was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; a congenital anomaly/birth defect and other important medical events.

Time frame:
From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) and AEs Leading to Study Discontinuation
ParticipantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
SAEs66
AEs Leading to Study Discontinuation129
Other pre-specifiedNumber of Participants With Laboratory Abnormalities Meeting Pre-Defined Criteria

The pre-defined criteria for laboratory parameters included: hemoglobin (\<9 grams per deciliter or decreases to \>=2 below baseline); platelets (\<75\*10\^3 cells per millimeter cube \[mm\^3\]); lymphocytes (\<0.5\*10\^3 cells per mm\^3); neutrophils (\<1\*10\^3 cells per mm\^3); aspartate aminotransferase and alanine aminotransferase (\>3\* upper limit of normal).

Time frame:
From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)
Reported as:
Count of participants · Participants
Number of Participants With Laboratory Abnormalities Meeting Pre-Defined Criteria
ParticipantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Number of Participants With Laboratory Abnormalities Meeting Pre-Defined Criteria3810
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs including temperature, systolic and diastolic blood pressure, and pulse rate were measured in a seated position after 5 minutes rest. Clinically significant change from baseline in vital signs were determined by the investigator.

Time frame:
From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Number of Participants With Clinically Significant Change From Baseline in Vital Signs00
Other pre-specifiedNumber of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Data

A single 12-lead ECG was performed after the participant has rested for at least 10 minutes quietly in the supine position. Clinically significant change from baseline in ECG data was determined by the investigator.

Time frame:
From start of study intervention to 28 days post last dose of study intervention (Up to Week 30)
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Data
ParticipantsAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) Data00

Adverse events

Collected over From start of study intervention up to 28 days after last dose of study intervention (Up to Week 30). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Abrocitinib 200 mg QD2/362 (0.6%)6/362 (1.7%)203/362 (56.1%)
Dupilumab 300 mg Q2W0/365 (0%)6/365 (1.6%)144/365 (39.5%)
Most frequent serious events
Showing 10 of 13
Most frequent serious events
EventAbrocitinib 200 mg QDDupilumab 300 mg Q2W
Cardio-respiratory arrestCardiac disorders1/3620/365
Cholecystitis acuteHepatobiliary disorders1/3620/365
COVID-19Infections and infestations1/3620/365
COVID-19 pneumoniaInfections and infestations1/3620/365
PneumoniaInfections and infestations1/3620/365
Upper limb fractureInjury, poisoning and procedural complications1/3620/365
Haemorrhage intracranialNervous system disorders1/3620/365
Alanine aminotransferase increasedInvestigations0/3621/365
Musculoskeletal chest painMusculoskeletal and connective tissue disorders0/3621/365
RhabdomyolysisMusculoskeletal and connective tissue disorders0/3621/365
Most frequent other events
Showing 10 of 23
Most frequent other events
EventAbrocitinib 200 mg QDDupilumab 300 mg Q2W
NauseaGastrointestinal disorders70/3628/365
HeadacheNervous system disorders47/36224/365
AcneSkin and subcutaneous tissue disorders46/36210/365
ConjunctivitisInfections and infestations8/36235/365
Dermatitis atopicSkin and subcutaneous tissue disorders17/36213/365
SARS-CoV-2 test positiveInvestigations15/36213/365
Oral herpesInfections and infestations9/36215/365
COVID-19Infections and infestations14/36212/365
NasopharyngitisInfections and infestations14/36212/365
Blood creatine phosphokinase increasedInvestigations14/36213/365

Baseline characteristics

Safety Analysis Set comprised of all participants randomly assigned to study intervention and who took at least 1 dose of study intervention.

Age, Continuous
Age, Continuous(Years)Abrocitinib 200 mg QDDupilumab 300 mg Q2WTotal
Mean36.6 ± 14.635.5 ± 13.336.0 ± 14.0
Sex: Female, Male
Sex: Female, Male(Participants)Abrocitinib 200 mg QDDupilumab 300 mg Q2WTotal
Female169161330
Male193204397
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Abrocitinib 200 mg QDDupilumab 300 mg Q2WTotal
Hispanic or Latino302757
Not Hispanic or Latino331337668
Unknown or Not Reported112
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Abrocitinib 200 mg QDDupilumab 300 mg Q2WTotal
American Indian or Alaska Native101
Asian6283145
Native Hawaiian or Other Pacific Islander101
Black or African American252651
White269248517
More than one race033
Unknown or Not Reported459
08

Study locations

151 sites
  • Total Skin & Beauty Dermatology Center, PC
    Birmingham, Alabama 35205, United States
  • Clinical Research Center Of Alabama
    Birmingham, Alabama 35209, United States
  • Alliance Dermatology & MOHS Center, PC
    Phoenix, Arizona 85032, United States
  • First OC Dermatology
    Fountain Valley, California 92708, United States
  • Ark Clinical Research
    Long Beach, California 90806, United States
  • Beach Allergy and Asthma Specialty Group, A Medical Corporation
    Long Beach, California 90808, United States
  • Wallace Medical Group, Inc
    Los Angeles, California 90056, United States
  • Empire Clinical Research
    Pomona, California 91767, United States
  • MedDerm Associates
    San Diego, California 92103, United States
  • University of California San Diego Dermatology
    San Diego, California 92122, United States
  • University Clinical Trials Inc.
    San Diego, California 92123, United States
  • Synergy Dermatology
    San Francisco, California 94132, United States
  • Wolverine Clinical Trials, Llc
    Santa Ana, California 92705, United States
  • Clinical Science Institute
    Santa Monica, California 90404, United States
  • Skin Care Research, LLC
    Boca Raton, Florida 33486, United States
  • Olympian Clinical Research
    Largo, Florida 33770, United States
  • Miami Dermatology & Laser Research, LLC
    Miami, Florida 33173, United States
  • Clinical Neuroscience Solutions, Inc.
    Orlando, Florida 32801, United States
  • Accel Research Sites - Pure Skin Dermatology & Aesthetics
    Orlando, Florida 32819, United States
  • Clinical Research Trials of Florida, Inc.
    Tampa, Florida 33607, United States
  • Olympian Clinical Research
    Tampa, Florida 33614, United States
  • Integrated Clinical Research
    West Palm Beach, Florida 33406, United States
  • One Health Research Clinic
    Norcross, Georgia 30093, United States
  • Sneeze, Wheeze & Itch Associates, LLC
    Normal, Illinois 61761, United States
  • Dundee Dermatology
    West Dundee, Illinois 60118, United States
  • Dawes Fretzin Clinical Research Group, LLC
    Indianapolis, Indiana 46250, United States
  • The South Bend Clinic Center for Research
    South Bend, Indiana 46617, United States
  • Epiphany Dermatology of Kansas, LLC
    Overland Park, Kansas 66215, United States
  • Avant Research Associates, LLC
    Crowley, Louisiana 70526, United States
  • MetroBoston Clinical Partners, LLC
    Brighton, Massachusetts 02135, United States
  • Onyx Clinical Research
    Flint, Michigan 48507, United States
  • Linden Road Imaging Center
    Flint, Michigan 48532, United States
  • Hamzavi Dermatology
    Fort Gratiot, Michigan 48059, United States
  • Regional Medical Imaging, P.C. ( Local X-Ray)
    Royal Oak, Michigan 48067, United States
  • Revival Research Institute, LLC
    Troy, Michigan 48084, United States
  • Skin Specialists, PC
    Omaha, Nebraska 68144, United States
  • Vivida Dermatology
    Las Vegas, Nevada 89148, United States
  • Psoriasis Treatment Center of Central New Jersey
    East Windsor, New Jersey 08520, United States
  • Boice-Willis Clinic, PA
    Rocky Mount, North Carolina 27804, United States
  • Carolina Research Center, Inc.
    Shelby, North Carolina 28150, United States
  • Oregon Medical Research Center
    Portland, Oregon 97223, United States
  • Paddington Testing Co, Inc.
    Philadelphia, Pennsylvania 19103, United States
  • Health Concepts
    Rapid City, South Dakota 57702, United States
  • Clinical Neuroscience Solutions, Inc.
    Memphis, Tennessee 38119, United States
  • International Clinical Research - Tennessee LLC
    Murfreesboro, Tennessee 37130, United States
  • Center for Clinical Studies, LTD. LLP
    Houston, Texas 77004, United States
  • Dermatology Clinical Research Center of San Antonio
    San Antonio, Texas 78229, United States
  • Acclaim Dermatology, PLLC
    Sugar Land, Texas 77479, United States
  • Jordan Valley Dermatology Center
    West Jordan, Utah 84088, United States
  • St George Dermatology and Skin Cancer Centre
    Kogarah, New South Wales 2217, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Box Hill Hospital
    Box Hill, Victoria 3128, Australia
  • Emeritus Research
    Camberwell, Victoria 3124, Australia
  • Skin Health Institute Inc.
    Carlton, Victoria 3053, Australia
  • Sinclair Dermatology
    East Melbourne, Victoria 3002, Australia
  • Melbourne Health Radiology
    Pakrville, Victoria 3050, Australia
  • The Royal Melbourne Hospital
    Parkville, Victoria 3050, Australia
  • MHAT Dobrich AD
    Dobrich, 9300, Bulgaria
  • MC Asklepii OOD
    Dupnitsa, 2600, Bulgaria
  • DCC Alexandrovska EOOD
    Sofia, 1431, Bulgaria
  • DCC Fokus-5 - Medical Establishment for Outpatient Care EOOD
    Sofia, 1463, Bulgaria
  • Military Medical Academy MHAT Sofia
    Sofia, 1606, Bulgaria
  • Dermatology Research Institute
    Calgary, Alberta T2J7E1, Canada
  • Alberta DermaSurgery Centre
    Edmonton, Alberta T6G1C3, Canada
  • CARE Clinic Ltd
    Red Deer, Alberta T4P-1K4, Canada
  • Dr. Chih-ho Hong Medical Inc
    Surrey, British Columbia V3R 6A7, Canada
  • Wiseman Dermatology Research Inc.
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Karma Clinical Trials, Inc.
    St. John's, Newfoundland and Labrador A1A 4Y3, Canada
  • Kingsway Clinical Research
    Etobicoke, Ontario M8X 1Y9, Canada
  • DermEffects
    London, Ontario N6H 5L5, Canada
  • Lynderm Research Inc.
    Markham, Ontario L3P 1X2, Canada
  • DermEdge Research
    Mississauga, Ontario L5H 1G9, Canada
  • North Bay Dermatology Centre
    North Bay, Ontario P1B 3Z7, Canada
  • The Centre for Clinical Trials
    Oakville, Ontario L6J 7W5, Canada
  • Dermatology Ottawa Research Centre
    Ottawa, Ontario K2C 3N2, Canada
  • SKiN Centre for Dermatology
    Peterborough, Ontario K9J 5K2, Canada
  • The Centre for Dermatology
    Richmond Hill, Ontario L4B 1A5, Canada
  • Medicor Research Inc
    Sudbury, Ontario P3A 1W8, Canada
  • Sudbury Skin Clinique
    Sudbury, Ontario P3C 1X8, Canada
  • Toronto Research Centre
    Toronto, Ontario M3H5Y8, Canada
  • Intermed groupe santé
    Chicoutimi, Quebec G7H 7Y8, Canada
  • Centre de Recherche Dermatologique du Quebec metropolitain
    Quebec, G1V 4x7, Canada
  • Centre de Recherche Saint-Louis
    Quebec, G1W4R4, Canada
  • Medicien
    Las Condes, Santiago, Region Metropolitana 7580150, Chile
  • MIRES (M Y F Estudios Clinicos Limitada)
    Nunoa, Santiago, Region Metropolitana 7750495, Chile
  • Vida lntegra
    Nunoa, Santiago, Region Metropolitana 7750495, Chile
  • Centro Radiologico Plaza Baquedano
    Santiago, Region Metropolitana 7500906, Chile
  • Centro Medico SkinMed Limitada
    Santiago, Region Metropolitana 7580206, Chile
  • Hospital Clinico Universidad de Chile
    Santiago, Region Metropolitana 8380456, Chile
  • Centro Internacional de Estudios Clinicos - CIEC
    Santiago, Region Metropolitana 8420383, Chile
  • Clínica Dermacross S.A.
    Santiago, Región Metropolitana 7640881, Chile
  • Terveystalo Tampere
    Tampere, 33100, Finland
  • Mehiläinen Neo
    Turku, 20520, Finland
  • Turun yliopistollinen keskussairaala
    Turku, 20520, Finland
  • Fachklinik Bad Bentheim
    Bad Bentheim, 48455, Germany
  • Klinikum Bielefeld Rosenhöhe
    Bielefeld, 33647, Germany
  • Klinische Forschung Dresden GmbH
    Dresden, 01069, Germany
  • IKF Pneumologie GmbH & Co KG
    Frankfurt am Main, 60596, Germany
  • SRH Wald-Klinikum Gera GmbH
    Gera, 07548, Germany
  • Studienzentrum Dr. med. Beate Schwarz
    Langenau, 89129, Germany

Showing the first 100 of 151 sites across 15 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, Hong HC, Katoh N, Valenzuela F, DiBonaventura M, Bratt TA, Zhang F, Clibborn C, Rojo R, Valdez H, Kerkmann U. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022 Jul 23;400(10348):273-282. doi: 10.1016/S0140-6736(22)01199-0. PubMed 35871814 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2020 to primary completion in Jul 2021, 13 months.

Results were first posted in Jul 2022, 11 months after primary completion.

Of 150 industry-sponsored phase 3 interventional studies under Dermatitis, Atopic, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 28. This study's 13 months is below that.

Counting every sponsor, half of 157 studies reached it within 18 months; a quarter within 13 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2020
First posted
Apr 14, 2020
StartActual
Jun 11, 2020
Primary completionActual
Jul 13, 2021
CompletionActual
Jul 13, 2021
Results first posted
Jul 8, 2022
Last update
Jul 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04345367
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Apr 14, 2020
Start date
Jun 11, 2020
Primary completion
Jul 13, 2021
Completion
Jul 13, 2021
Results posted
Jul 8, 2022
Last update
Jul 8, 2022

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abrocitinib

Start the discussion